Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab.
about
Update on the management of inflammatory bowel disease: specific role of adalimumab.Review article: remission rates achievable by current therapies for inflammatory bowel disease.Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy.Tailoring anti-TNF therapy in IBD: drug levels and disease activity.Management of inflammatory bowel disease in poor responders to infliximab.Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.Optimizing biological therapy in Crohn's disease.Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases: The Missing Link.Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.Evidence-based use of anti-TNFα therapy in Crohn's disease; where are we in 2011?Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.Funding a smoking cessation program for Crohn's disease: an economic evaluation.Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials.Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn's disease.Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's diseaseCrohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study
P2860
Q35186975-4C4D6CC0-EB5A-4211-ADAC-0ABE3E4FE47EQ37842605-4EEF88D4-9269-47D1-9D32-7C5DD2E99A0CQ37871625-D33DD49C-E3B7-4E1A-9F40-93C7B476D51DQ38176154-00153696-B39F-43BE-AADE-419700B525A2Q38254573-560ABA34-A353-458E-B74D-99AEAF69A6B1Q38337716-B675D5BD-D21F-47A6-8FE6-F910F2B42BAFQ38344622-BD804CF4-24B7-4817-AC36-EE3B2CD6197AQ38501680-81051CD6-0372-457B-9505-9A18A2A6B39BQ38608158-7965E90C-102F-480E-8A62-00A5BFBAE306Q38822920-215556FE-BDFD-48E5-85F7-D825B24CE264Q38826447-38555D30-6C56-47B4-899D-7CD2F1674555Q39306418-705BDDA8-0534-4DB3-9AE0-3BB674A3DD0DQ41060236-5005CA44-3047-4952-8980-26193A809246Q41640821-B4957B33-957F-4FCA-8375-5234C47F2FD0Q48172992-60BD84DB-1DC2-4D0A-8193-FBB8F0DA9AA9Q51039528-F11453F0-B69D-49B5-B3FB-EB19171E9073Q52561556-AAE12824-2B10-445B-BF58-AE14A49FDAC3Q53572128-EA1348D6-4D47-4254-A5EA-4199458DAC6BQ59120251-8F2042D2-2B83-40B3-9EEA-BED1D2E9A54CQ59120257-B69B85B0-2D70-4166-BBD6-CADA0FB889FB
P2860
Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Systematic review: the short-t ...... discontinuation of infliximab.
@en
Systematic review: the short-t ...... discontinuation of infliximab.
@nl
type
label
Systematic review: the short-t ...... discontinuation of infliximab.
@en
Systematic review: the short-t ...... discontinuation of infliximab.
@nl
prefLabel
Systematic review: the short-t ...... discontinuation of infliximab.
@en
Systematic review: the short-t ...... discontinuation of infliximab.
@nl
P2093
P1476
Systematic review: the short-t ...... discontinuation of infliximab
@en
P2093
R Panaccione
S J Heitman
S M Devlin
P304
P356
10.1111/J.1365-2036.2009.04101.X
P407
P577
2009-07-22T00:00:00Z